Drugs / Dendritic Cell (DC1) Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05378464 | May 2022 → Aug 2026 | HER2 positive breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dendritic Cell (DC1) Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05378464 ↗ |
| Modality | Vaccine | “Participants will receive a DC1 vaccine injection at 1.0-2.0 x 10\^7 cells, either to groin lymph notes or to tumor if accessible once a week for 3 weeks on days 1, 8 and 15.” NCT05378464 ↗ |
| Route | Other | “either to groin lymph notes or to tumor if accessible once a week for 3 weeks on days 1, 8 and 15.” NCT05378464 ↗ |